Autoantibodies Linked to Persistent Long COVID Symptoms, New Research Shows
Recent studies coordinated by UMC Utrecht and Amsterdam UMC have revealed a potential key driver of long COVID: autoantibodies – antibodies that mistakenly target the body’s own tissues. Research indicates these autoantibodies can induce symptoms resembling chronic pain when transferred to animal models, strengthening the hypothesis that they play a direct role in the illness and opening avenues for targeted immunological therapies.
Understanding the Autoimmune Connection in Long COVID
Over the past few years, evidence has been mounting suggesting that long COVID, similarly known as post-COVID syndrome, may have an autoimmune origin. Affecting more than 10% of individuals following a SARS-CoV-2 infection, the condition is characterized by an abnormal immune response where the body attacks its own tissues. However, until now, a definitive link demonstrating that these autoantibodies directly cause symptoms has been lacking.
The Broad Spectrum of Long COVID Symptoms
Long COVID presents with a wide range of symptoms, including extreme fatigue, post-exertional malaise (PEM), widespread pain and cognitive dysfunction, often referred to as “brain fog.” Despite its prevalence, the underlying biological mechanisms remain poorly understood. Previous research had identified immune alterations and the presence of autoantibodies, but their precise role in the disease was unclear.
Study Details: Transferring Symptoms to Mice
Researchers designed an experiment where immunoglobulin G (IgG), a key type of antibody, was extracted from the blood of 34 patients with long COVID. When these samples were injected into mice, the animals developed persistent hypersensitivity, mirroring the sensation of prolonged pain. This effect lasted for at least two weeks, indicating a sustained impact of the antibodies. Remarkably, IgG collected from the same patients two years later reproduced the same symptoms in mice.
Heterogeneity of Long COVID: Different Subgroups Identified
The research team further investigated the diversity of long COVID by analyzing blood samples in detail. They identified different subgroups of patients based on biological markers related to brain damage – such as GFAP and NFL – and immune system activation, particularly interferon-β. Each group exhibited distinct molecular profiles, reinforcing the idea that long COVID isn’t a single clinical entity. When autoantibodies from these different subgroups were analyzed in animal models, varying symptom patterns were observed, further confirming the disorder’s heterogeneity.
“This finding supports the idea that persistent Covid is not a single disease, but rather a heterogeneous disease with different biological factors,” stated Dr. Jeroen den Dunnen, a co-director of the study.
Multiple Autoantibody Targets Identified
The analysis revealed that patients with long COVID have elevated levels of autoantibodies targeting multiple proteins within their own bodies. These targets include proteins crucial for immune system regulation, neuronal communication, and cellular metabolism. Many of these autoantibodies persist over time and vary between patient subgroups, adding to the complexity of the clinical picture.
Converging Evidence from Multiple Research Groups
Researchers emphasize that these findings are not isolated. “What is really surprising,” they explain, “is that three independent research groups have recently published similar findings, reinforcing the emerging evidence of the autoimmune signature of persistent Covid.” They also note that similar antibody-induced symptom transfer has been observed in other conditions with comparable symptoms, such as fibromyalgia, suggesting shared immunological mechanisms.
Future Therapeutic Strategies
While acknowledging limitations such as the small sample size and single-center nature of the study, researchers believe the results provide strong evidence for the active role of IgG autoantibodies in symptom development. This advancement opens the door to new therapeutic strategies focused on eliminating or neutralizing these harmful antibodies, potentially through techniques like immunoadsorption, plasmapheresis, or targeted immune therapies. UMC Utrecht is currently leading research into potential drug treatments for Long COVID, in collaboration with researchers in the United Kingdom, Italy, and Spain. Stichting Long COVID is providing funding to accelerate this research.
this study represents a significant step forward in understanding long COVID, a disease that continues to pose major medical and social challenges. As the mechanisms are further explored, these findings could contribute to developing more effective and personalized treatments for those suffering from its long-term effects.
*The contents of this article are prepared by journalists specialized in health and endorsed by a committee of top-level experts. However, we recommend that the reader consult any health-related questions with a healthcare professional.
Worth a look